glp-1 and xarelto Cardiovascular Protection with a Long-Acting Receptor Agonist Liraglutide: An Experimental Update GLP-1 & Microdosing | AgelessRx

A series of recent studies might provide some clues to this question

The American Diabetes Associations position that metformin should remain the first-line treatment for most type 2 diabetes cases is partly driven by this cost advantage at roughly $120 per year versus over $11,000 annually for Rybelsus, metformins modest efficacy is justified for 90% of people starting type 2 diabetes treatment

L-cells express various receptors for nutrient sensing including G protein-coupled receptors (GPRs)

Lower doses mean less appetite suppression, which means food choices become even more consequential for weight management outcomes

(May 16 2024) Coming off GLP-1s slowly could be the key to preventing weight regain

Jannah N, Hild J, Gallagher C, Dietz W (2018) Coverage for obesity prevention and treatment services: analysis of medicaid and state employee health insurance programs